This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen submitted an application to the Food and Drug Administration for approval of its biosimilar drug ABP 501 on Nov. 25. ABP 501 is designed as a lower-cost version of Humira, which is approved to treat nine conditions including arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based AbbVie, typically costs $20,000 per year Read More →
Thousand Oaks-based Amgen scored another major victory Nov. 19. European regulators approved experimental drug Kyprolis on Thursday for patients who have received at least one prior treatment for multiple-myeloma. Kyprolis was the cornerstone of Amgen’s $10.4 billion buyout of Onyx Pharmaceuticals in 2013. Multiple-myeloma is a form of blood cancer that forms in plasma cells Read More →
Thousand Oaks-based biotech giant Amgen announced on Nov. 6 that the Food and Drug Administration will review a new treatment for patients with chronic kidney disease. The new drug, Etelcalcetide, works by suppressing the secretion of a parathyroid hormone. The drug is administered intravenously three times per week at the end of a dialysis session. Read More →
Thousand Oaks biotech giant Amgen blew Wall Street away when it released third quarter earnings on Oct. 28. Amgen beat analyst revenue estimates by posting revenues of $5.72 billion, compared to the $5.23 billion analysts expected. That’s up from about $5 billion during last year’s third quarter. Net income increased to $1.86 billion during the Read More →
The U.S. Food and Drug Administration on Oct. 27 approved Amgen’s cancer immunotherapy drug Imlygic for use in patients with the most deadly types of skin cancer. Imlygic, which is the first immunotherapy like this to gain approval for use in the U.S., is a genetically modified herpes virus that is designed to replicate itself Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
